Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

1. Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry
2. Introduction of allergenic foods after treatment with omalizumab
3. Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial.

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

And for those currently listening to the audio version, we are now releasing a video versions of AllergyTalk! Please visit the ACAAI YouTube channel at https://www.youtube.com/@allergists

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Paging ChatGPT: Potential and Limitations: Can ChatGPT provide parent education for oral immunotherapy? 

2024 Consensus Report: A New Consensus Definition for Anaphylaxis: Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project. 

Zileuton Prevents Food Allergen Induced Anaphylaxis in Mice: Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice.

Please rate our podcast on Apple Podcasts or YouTube!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai.

For more information on this topic, please visit:

Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332

Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034

Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918

Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014

Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

This podcast miniseries is supported by Genentech.

Host Gerald Lee, MD, FACAAI, is joined by Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai.

For more information on this topic, please visit:

Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332

Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034

Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918

Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014

Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

This podcast miniseries is supported by Genentech.

Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine.

For more information on this topic, please visit:

Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332

Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034

Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918

Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014

Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

This podcast miniseries is supported by Genentech.

Articles Reviewed:

• Prenatal indoor PM2.5 exposure is associated with worse maternal asthma health and lung function
• Want to help your patients with food allergy anxiety? Do proximity challenges!
• Tiotropium initiation and dementia risk in chronic obstructive pulmonary disease

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• Integrated phase 1 pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection
• Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies
• Peanut oral immunotherapy in children with high-threshold peanut allergy

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections
• A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study
• Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures:

Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• Association of Allergy Specialty Care and Asthma Outcomes for Medicaid-Enrolled Children
• Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children
• Anaphylactic degranulation by mast cells requires the mobilization of inflammasome components

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures:  Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• Persistent cat ownership and asthma in a longitudinal study of Puerto Rican youth
• The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children – A pivotal phase III trial
• Awareness and application of United States food allergy prevention guidelines among pediatricians and other clinicians

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Sarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to discuss advice on landing your first position. Continuing the conversation from Part 1, in this episode, our experts cover how to narrow down your choices, make sense of contracts and negotiations, decide whether to involve a contract lawyer, and plan a smooth transition into your next chapter.

Earn CME credit for listening to this episode! Free for College members!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures: Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to disclose Kylie Jungles, MD: No relevant financial relationships with ineligible companies to disclose Melinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to share essential tips for fellows-in-training starting their job search. Learn how to choose the right practice setting, create a strategic job search plan, and interview with confidence.

Earn CME credit for listening to this episode! Free for College members!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures: Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to disclose Kylie Jungles, MD: No relevant financial relationships with ineligible companies to disclose Melinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients!

Michael S. Blaiss, MD, Clinical Professor of Pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines. Dr. Blaiss was joined by host Dr. Gerald Lee, MD, FACAAI.

Resources:

• FDA Drug Safety Communication on Cetirizine and Levocetirizine
• ACAAI Advice on Speaking Points Regarding FDA Alert

Previous articles describing this side effect:

• Unbearable Pruritus After Withdrawal of (Levo)cetirizine
• Pruritus after discontinuation of cetirizine

Make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• A novel syndrome of silent rhinovirus-associated bronchoalveolitis in children with recurrent wheeze
• Effects of moderate- versus vigorous-intensity exercise training on asthma outcomes in adults
• Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Sarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices
• Forecasting daily total pollen concentrations on a global scale
• Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Iris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial
• Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study
• Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

Speaker Disclosures:  Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Iris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Articles Reviewed:

• The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry
• Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders
• Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion

The speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant: Pharming, Kaleo Speaker: CSL, Takeda, Kaleo

Read archived issues of AllergyWatch®.

Earn CME credit for listening to this episode! Free for College members!

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org!

The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

For information about CME credit, head over to http://education.acaai.org/allergytalk

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins. 

Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food.

Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Hernandez Trujillo:

• Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda
• Consultant/Speaker: Kaleo
• Consultant: Allergy & Asthma Network, Pharming
• Speaker: CSL, Takeda

Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI

Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Employ strategies for long-term prophylaxis.

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD

Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda

Researcher: Astria, Ionis, Intellia

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

This podcast miniseries is supported by a grant from Takeda.

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI

Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI

This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Create effective treatment plans for their specific population (minority, rural, urban)

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Jonathan A. Bernstein, MD, FACAAI

Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda

Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.

Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI

This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed.

Learning Objective:

After listening to this podcast episode, participants should be better able to:

• Diagnose pediatric HAE accurately

References:

1. Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767.
2. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533.
3. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3
4. Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022

Speaker Disclosures:

Kristin C. Sokol, MD, MS, MPH, FACAAI

Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD

Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda

Researcher: Astria, Ionis, Intellia

Timothy J. Craig, DO, FACAAI

Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda

Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda

Independent Contractor: Kalvista, Phavaris

Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda

Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda

This podcast miniseries is supported by a grant from Takeda.

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

CRISPR Gene-Editing Therapy for Hereditary Angioedema

Reviewed by Samantha knox

CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.

Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975.

New Peanut Allergy Rare After Peanut Introduction in Infants

Reviewed by Sarah Spriet

Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants

Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.

IgE to Food Allergens and Cardiovascular Mortality

Reviewed by Gerry Lee

IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis

Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A, Wilson JM. IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis. J Allergy Clin Immunol. 2024 Feb;153(2):471-478.e3. doi: 10.1016/j.jaci.2023.09.038. Epub 2023 Nov 9. PMID: 37943208; PMCID: PMC10922097.

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended KA)

For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Reviewed by Iris Otani

Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial.

Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839.

Clinical Remission in a Real-World Severe Asthma Registry

Reviewed by Tim Chow

Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry.

McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453.

More Evidence Against Using Corticosteroids for Anaphylaxis

Reviewed by Iris Otani

Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data.

Delli Colli L, Al Ali A, Gabrielli S, Delli Colli M, Mule P, Lawson B, Clarke AE, Morris J, Gravel J, Lim R, Chan ES, Goldman RD, O'Keefe A, Gerdts J, Chu DK, Upton J, Hochstadter E, Bretholz A, McCusker C, Zhang X, Benor S, Simons E, Abrams EM, Protudjer JLP, Ben-Shoshan M. Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphylaxis REgistry data. Ann Allergy Asthma Immunol. 2023 Dec;131(6):752-758.e1. doi: 10.1016/j.anai.2023.08.606. Epub 2023 Sep 7. PMID: 37689113.

Please rate our podcast on Apple podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

You can also earn CME credit by listening to this podcast! For information about CME credit head over to education.acaai.org/allergywatch. If you want to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis

Dr. Fineman has nothing to disclose

Dr. Chow has been an advisor for Sarepta Therapeutics (relationship has ended)

Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma

Host: Gerald B. Lee, MD, FACAAI

Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US
• Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
• Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
• Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

Leonard B. Bacharier, MD, FACAAI

Advisor: DBV Technologies

Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Researcher: AstraZeneca, Sanofi

Speaker: Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI

Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.

Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma

Host: Gerald B. Lee, MD, FACAAI

Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US
• Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
• Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
• Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference:

Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI

Advisor: Genentech, Regeneron, Sanofi

Leonard B. Bacharier, MD, FACAAI

Advisor: DBV Technologies

Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi

Researcher: AstraZeneca, Sanofi

Speaker: Regeneron, Sanofi

This podcast miniseries is supported by a grant from AstraZeneca.

Episode 1: The Limitations of Bronchodilator Only Rescue Therapy

Host: Gerald B. Lee, MD, FACAAI

Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI

Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.

Learning Objectives:

• Expose the prevalence of asthma and exacerbations in the US
• Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic
• Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies
• Analyze the latest expert opinion on treatment of asthma to mitigate morbidity

Reference:

Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.

Speaker Disclosures:

Gerald B. Lee, MD, FACAAI

No relevant financial relationships with ineligible companies to disclose

William C. Anderson III, MD, FACAAI

Advisor: Genentech, Regeneron, Sanofi

Alan P. Baptist, MD, MPH, FACAAI

Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi

Researcher: AstraZeneca, Novartis, Regeneron

This podcast miniseries is supported by a grant from AstraZeneca.

Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Gut microbiota maturity mediates the protective effect of siblings on food allergy.

Duration of skin prick test refractory period following food-induced allergic reactions.

Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study.

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis.

Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt

Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy

Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Outcomes of oral food challenges in a real-world setting, with predictors of outcomes.

Severe food allergy reactions are associated with α-tryptase.

Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations.

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis.

Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt

Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy

As the fall welcomes a new class of allergy/immunology fellows, the graduating fellows are studying for the fall ABAI board certification exam. I’m excited to be joined by the editorial team of the newly released 5th edition of the ACAAI Review of the Allergy & Immunology Boards, where we’ll talk about how you can prepare for the upcoming board exam!

Guests:

Joyce Yu, MD Associate Professor of Pediatrics Director, Food Allergy Center Division of Allergy, Immunology and Rheumatology Columbia University Irving Medical Center

Ben Prince, MD, MSCI Associate Professor of Pediatrics Associate Division Chief of Research Division of Allergy-Immunology The Ohio State University College of Medicine

Resources for Board Review:

Exam Blueprint

ACAAI FIT and Board Review Resources (including the board review book)

AIM Self-Assessment: Volume One (2023)

AAAAI Allergy/Immunology Self Assessment

For information about CME credit, head over to http://education.acaai.org/allergytalk

Please rate our podcast on Apple Podcasts!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has been a speaker for Novartis.

Dr. Prince is a Data Monitoring Committee Member for Eli Lilly

Dr. Yu has no relevant disclosures.

Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial. 

Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation. 

Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Spriet have nothing to disclose

Dr. Fineman: Research: DBV, Novartis, Alladapt

Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

The protective effect of moderate maternal peanut consumption on peanut sensitization and allergy. 

Hymenoptera venom skin testing: Adopting an accelerated test protocol. 

Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Spriet have nothing to disclose

Dr. Fineman -  Research: DBV, Novartis, Alladapt

Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk .  To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.

Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis.

Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Chow have nothing to disclose

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: An integrated analysis.

Wildfires and the Changing Landscape of Air Pollution-related Health Burden in California.

Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Chow have nothing to disclose

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Today we joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk .

To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch .

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Food Allergy Management for Adolescents Using Behavioral Incentives: A Randomized Trial.

Early, continuing exposure to cow's milk formula and cow's milk allergy: The COMEET study, a single center, prospective interventional study.

Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Rathkopf have nothing to disclose

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Today we are joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk .

To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch .

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

 Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.

Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.

The impact of prenatal dog keeping on infant gut microbiota development.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Rathkopf have nothing to disclose

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk

To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.

Prospective evaluation of tolerance to unheated milk-boiled egg after baked milk-egg tolerance under 2 years.

Multiscale study of the oral and gut environments in children with high- and low-threshold peanut allergy.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Knox have nothing to disclose

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

You can earn CME credit by listening to this podcast! For information about CME credit, go to https://education.acaai.org/allergytalk.

To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch.

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Race and ethnicity define disparate clinical outcomes in chronic rhinosinusitis.

Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study.

Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Knox have nothing to disclose

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Articles Reviewed:

In Kids With Allergic Rhinitis, Remember To Address Sleep Problems!

Allergic disease, sleep problems, and psychological distress in children recruited from the general community.

Azithromycin as an Option for Poorly Controlled Childhood Asthma

 Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.

Data Suggest ‘Real-World Benefit’ of Early Introduction

Changes in Australian food anaphylaxis admission rates following introduction of updated allergy prevention guidelines.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Joshi has the following disclosures:

• Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
• Clinical trial funding: GlaxoSmithKline Sanofi

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!

For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Articles Reviewed:

Combined ICS/SBA Reduces Asthma Exacerbations

Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.

CRSwNP Patients have Impaired Sense of Smell and Taste

Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.

Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.

Anti-dsDNA IgG May Predict Nasal Polyp Recurrence

Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Joshi has the following disclosures:

• Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent
• Clinical trial funding: GlaxoSmithKline Sanofi

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Today we joined by Dr. Vivan Hernandez-Trujillo, MD from Nicklaus Children’s Hospital in Miami, Florida where we review the July-Aug 2022 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Combining Discordant Serum IgE and Skin Testing Improves Diagnostic and Therapeutic Accuracy for Hymenoptera Venom Hypersensitivity Immunotherapy.

Safety of Live Attenuated Influenza Vaccine in Children With Asthma.

Obesity alters pathology and treatment response in inflammatory disease.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Hernandez-Trujillo: 

Speaker Takeda, CSL

Advisory boards Takeda, Regeneron, Sanofi

Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network

Dr. Fineman:

Speaker: Takeda; Research: Aimmune, DBV, Biocryst

For today’s episode we will be reviewing three articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.

Is Alpha-Gal Really a Problem in Patients with Food Allergy? Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018.

Family history alone isn’t a Risk Factor for Peanut Allergy Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy.

Peripheral eosinophil counts: a moving target Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In second part of a 2 part series, we will discuss important considerations in implementing omalizumab for food allergy in your practice.

Speakers:

Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study.

Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.

Important Links:

Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382

Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose.

Dr. Chinthrajah has consulted for Genentech and Novartis.

Dr. Vickery has consulted for Genentech and Novartis

Speakers:

Dr. Robert Wood, MD, the Julie and Neil Reinhard Professor of Pediatric Allergy and Immunology and Division Director at Johns Hopkins University School of Medicine and Primary Investigator of the OUtMATCH study.

Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study.

Important Links:

Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, YovetichN, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25.

https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382

Updated FDA label for omalizumab:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose.

Dr. Wood has consulted for Genentech.

Dr. Vickery has consulted for Genentech and Novartis

Articles Reviewed:

Tezepelumab Reduces Exacerbations – Even at Lower Eosinophil Counts

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

Predicting Response to Aspirin Therapy in NSAID-ERD

Biomarkers for predicting response to long-term high dose aspirin therapy in aspirin-exacerbated respiratory disease.

Can Technology Aid in Asthma Therapy Adherence?

The Impact of Patient Self-Monitoring Via Electronic Medication Monitor and Mobile App Plus Remote Clinician Feedback on Adherence to Inhaled Corticosteroids: A Randomized Controlled Trial.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Metabolic Changes During Anaphylaxis Vary by Triggers and Severity

Characterization of anaphylaxis reveals different metabolic changes depending on severity and triggers.

Is IBS Caused by Local Food Allergy in the Intestine?

Local immune response to food antigens drives meal-induced abdominal pain.

Biologics: To Stop or Not to Stop, That Is the Question

Asthma Patients Who Stop Asthma Biologics Have a Similar Risk of Asthma Exacerbations as Those Who Continue Asthma Biologics.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Articles Reviewed:

When an asthma patient doesn’t respond to biologic, what should we do?

Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy.

Can we reduce lung function loss in asthma?

Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.

Airborne peanut doesn’t cause clinical significant reactions

Peanuts in the air - clinical and experimental studies.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, Alladapt, Novartis

Articles Reviewed:

AZT Improves Outcomes and Lowers Costs in Uncontrolled Asthma

The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.

Cefazolin Should Be Used in Most Penicillin Allergic Patients

Assessment of the Frequency of Dual Allergy to Penicillins and Cefazolin: A Systematic Review and Meta-analysis.

Consider IV Fluids Early if Anaphylaxis Doesn’t Respond to Epinephrine

Cardiovascular changes during peanut-induced allergic reactions in human subjects.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

At the time of recording, the speakers had the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Today we are again joined by Dr. Vivian Hernandez-Trujillo from Nicklaus Children’s Hospital and will be reviewing the July-Aug 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Hernandez-Trujillo: 

Speaker Takeda, CSL

Advisory boards Takeda, Regeneron, Sanofi

Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Today we are again joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations.

Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.

Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Montanaro has done research with AstraZeneca, Regeneron, Theravance, and Teva

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst, Novartis

Today we are joined by Dr. Anthony Montanaro from Oregon Health & Science University and will be reviewing the Jan-Feb 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. 

You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!

Articles Reviewed:

Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis.

First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.

Differences in oral food challenge reaction severity based on increasing age in a pediatric population.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Description: Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.  

Learning Objectives:

1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma

References:              

1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose

This podcast series is supported by Sanofi Regeneron.

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose Anjeni Keswani, MD: Nothing to disclose

This podcast series is supported by Sanofi Regeneron.

Today’s speakers have the following disclosures:

Gerald Lee, MD: Nothing to disclose

Maha Mahdavinia, MD, PhD: Consulting, Fee: Optinose

Anjeni Keswani, MD: Nothing to disclose

This podcast series is supported by Sanofi Regeneron.

Disparities in Atopic Dermatitis Miniseries

Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI

The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis.

This podcast series is supported by Pfizer.

Disparities in Atopic Dermatitis Miniseries

Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI

The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis.

This podcast series is supported by Pfizer.

Disparities in Atopic Dermatitis Miniseries

Host: Payel Gupta, MD, FACAAI Expert: Anil Nanda, MD, FACAAI Expert: Andrew Alexis, MD, MPH Expert: Marcella Aquino, MD, FACAAI

The miniseries is hosted by Payel Gupta, MD,  a triple board-certified specialist and the Medical Director for Allergy, Asthma, Immunology & ENT at LifeMD.com. She is practicing in New York City and is an assistant clinical professor at SUNY Downstate Medical Center and Clinical Instructor at Mount Sinai Medical Center.  She is a volunteer national spokesperson for the American Lung Association and co-host of The Itch Podcast. Joining her are Anil Nanda, MD, who is in private community practice at the Asthma and Allergy Center in Lewisville and Flower Mound, Texas and is Clinical Associate Professor of Medicine, at the Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, TX; Andrew F. Alexis, MD, MPH, who is the Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Professor of Clinical Dermatology at Weill Cornell Medical College in New York City. He is the former Chair of the Department of Dermatology at Mount Sinai Morningside and Mount Sinai West. Having served as Director of the first-of-its-kind Skin of Color Center for over 15 years, his work has helped to advance patient care, research, and education pertaining to dermatologic disorders that are prevalent in populations with skin of color; and Marcella Aquino, MD, who is an Associate Professor of Pediatrics at the Warren Alpert Medical School of Brown University and staff at Rhode Island Hospital/Hasbro Children’s Hospital. Her interests include allergic skin diseases particularly allergic contact dermatitis, atopic dermatitis, and drug allergy. She has presented on these topics at national meetings and published in textbooks and peer reviewed journals with a focus on contact dermatitis including patch testing, the role of contact dermatitis in atopic dermatitis patients, drug allergy challenges/desensitizations and the use of simulation for the instruction of anaphylaxis/allergic emergencies. Dr. Aquino was awarded an implementation grant by the ACAAI Foundation looking a multi-level contributing factors to racial and ethnic disparities in urban children in asthma and atopic dermatitis.

This podcast series is supported by Pfizer.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

 A Behavior Change Intervention Aimed at Increasing Physical Activity Improves Clinical Control in Adults With Asthma: A Randomized Controlled Trial.

The Predicative Clinical Features Associated with Chronic Cough That Has a Single Underlying Cause.

 Trends in US hospitalizations for anaphylaxis among infants and toddlers: 2006 to 2015.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Early life acetaminophen exposure, glutathione S-transferase genes, and development of adolescent asthma in a high-risk birth cohort.

Health Services Utilization Is Increased in Poor Perceivers of Bronchoconstriction and Hyperinflation in Asthma.

Milk allergy most burdensome in multi-food allergic children.

Episode may include interview clips from a patient on how they/their children received the diagnosis of PIDD and what barriers they experienced in receiving the diagnosis of PIDD and what barriers they experienced in receiving the diagnosis of PIDD.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics.

Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.

Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype.

Novel airway smooth muscle-mast cell interactions and a role for the TRPV4-ATP axis in non-atopic asthma.

Immunoglobulin G and immunoglobulin G subclass concentrations differ according to sex and race.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article Links:

Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE. 

Performance Characteristics of Spirometry With Negative Bronchodilator Response and Methacholine Challenge Testing and Implications for Asthma Diagnosis.

Real-World Effectiveness and the Characteristics of a "Super-Responder" to Mepolizumab in Severe Eosinophilic Asthma. 

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee has nothing to disclose

Dr. Kalangara Speaker and Consultant: GlaxoSmithKline

Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging discussion with the opportunity for ongoing conversation about today's topic!

Article links:

Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis. 

Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Changes in asthma severity in the first year of school and difficulty learning to read.

IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

Sialylation of immunoglobulin E is a determinant of allergic pathogenicity.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Reintroduction failure after negative food challenges in adults is common and mainly due to atypical symptoms.

Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy.

Home self-monitoring in patients with asthma using a mobile spirometry system.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

For today’s episode we will be reviewing three articles from the July-August 2020 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key takeaways with the opportunity for ongoing conversation about today's topic!

Article links:

Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis.

Trends and Disparities in Asthma Biologic Use in the United States.

Treatment Effect of Omalizumab on Severe Pediatric Atopic Dermatitis: The ADAPT Randomized Clinical Trial.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article links:

Prenatal and Early-Life Exposure to Indoor Air-Polluting Factors and Allergic Sensitization at 2 Years of Age

Impact of Sinus Surgery on Type 2 Airway and Systemic Inflammation in Asthma

Long-term Sublingual Immunotherapy for Peanut Allergy in Children: Clinical and Immunologic Evidence of Desensitization

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Please watch out for continued discussion on this topic in the ACAAI Community on DocMatter, we’ll have key talk takeaways and an engaging question with the opportunity for ongoing conversation about today's topic!

Article links:

Earlier Ingestion of Peanut After Changes to Infant Feeding Guidelines: The EarlyNuts Study

Effect of Sleep Deprivation and Exercise on Reaction Threshold in Adults With Peanut Allergy: A Randomized Controlled Study

Treatment With a Platelet-Activating Factor Receptor Antagonist Improves Hemodynamics and Reduces Epinephrine Requirements, in a Lethal Rodent Model of Anaphylactic Shock

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara has nothing to disclose

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.

The ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Khan receives royalties from a book on drug allergy testing published by Elsevier.

Article Links:

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.

Altered Viscosity of Nasal Secretions in Postnasal Drip.

Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a "hit-and-run" mechanism.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Article links:

Loss of bronchoprotection with ICS plus LABA treatment, β-receptor dynamics, and the effect of alendronate.

Step-Up Therapy in Black Children and Adults with Poorly Controlled Asthma.

Unexpected and unintended cure of habit cough by proxy.

Please rate our podcast on iTunes!

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

This podcast is supported by an educational grant from Merck & Co., Inc.

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron

Purvi Parikh, MD

Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca

Mandel Sher, MD

Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

This podcast is supported by an educational grant from Merck & Co., Inc.

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron

Purvi Parikh, MD

Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca

Mandel Sher, MD

Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

This podcast is supported by an educational grant from Merck & Co., Inc.

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Kevin Murphy, MD Honoraria: AstraZeneca, Genentech, Novartis, Sanofi, Regeneron

Purvi Parikh, MD

Honoraria: AstraZeneca, Takeda, Genentech/Novartis, Aimmune; Contracted research: AstraZeneca

Mandel Sher, MD

Advisory Committee, Consulting Fee: Merck; Speaker, Honorarium: Optinose; Consulting, Fee: NeRRe; Clinical Investigator, Contracted Research: Attenua, Merck, NeRRe

We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk

Article Links:

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.

Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study.

Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk

Article Links:

Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.

Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children. 

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. 

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Drs. Lee and Kalangara have nothing to disclose.

Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Dr. Lee has no relevant disclosures.

At the 2019 ACAAI Annual Meeting in Houston, Texas we interviewed the leaders of the College on how the ACAAI helps its members and what to expect for 2020! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Mahr: 

Research / Consultant / Advisory Board / Speaker / Honorarium:

Aimmune, ALK, AZ, Boeringer-Ingelheim, Kaleo, GSK,  Optinose, Sanofi-Genzyme - Regeneron

Dr. Meadows:

Speaker: Regeneron, Pfizer, AZ, GSK, Optinose

Consultant: Aimmune

Dr. Lee:

No relevant disclosures

Please give us feedback, corrections, and suggestions!

If you have a topic you’d like to cover in a future podcast, let us know at  allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Shih was on advisory board for Teva and Tekeda.

Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms

https://www.ncbi.nlm.nih.gov/pubmed/30819281

New-Onset Asthma in Adults: What Does the Trigger History Tell Us?

https://www.ncbi.nlm.nih.gov/pubmed/30240884

Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States

https://www.ncbi.nlm.nih.gov/pubmed/30277796

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

https://www.ncbi.nlm.nih.gov/pubmed/30488542

Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity

https://www.ncbi.nlm.nih.gov/pubmed/30170124

New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis

https://www.ncbi.nlm.nih.gov/pubmed/30684739

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from AstraZeneca.

Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.

• The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy. https://www.ncbi.nlm.nih.gov/pubmed/30408255
• Oral food challenge failures among foods restricted because of atopic dermatitis. https://www.ncbi.nlm.nih.gov/pubmed/30326323
• The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype. https://www.ncbi.nlm.nih.gov/pubmed/30787169

Please give us feedback, corrections, and suggestions!

Email feedback to: allergytalk@acaai.org

ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Today’s speakers have the following disclosures:

Dr. Lee was on an advisory board for Teva.

Dr. Kalangara has received consulting fees from Astra Zenica.

Dr. Fineman  Speaker: AstraZenca, Boehringer Ingelheim, Shire Research: Aimmune, DBV, Shire, Regeneron.